Impact News +++ Omeros Corporation Reports Third Quarter 2025 Financial Results (Business Wire) +++ OMEROS Aktie -3,23%

KODIAK SCIENCES Aktie

>KODIAK SCIENCES Aktienkurs

16.195 EUR (Tradegate)

Ask: 16.3 EUR / 170 Stück

Bid: 16.09 EUR / 180 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>KODIAK SCIENCES Performance

1 Woche: +12,4%

1 Monat: +73,2%

3 Monate: +138,4%

6 Monate: +407,0%

1 Jahr: +263,9%

laufendes Jahr: +82,5%

>KODIAK SCIENCES Aktie

Name:

KODIAK SCIENCES DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US50015M1099 / A2N6P0

Symbol/ Ticker:

K27 (Frankfurt) / KOD (NASDAQ)

Kürzel:

FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD

Index:

Webseite:

https://kodiak.com/

Profil:

Kodiak Sciences Inc. is a biopharmaceutical compan..
>Volltext..

Marktkapitalisierung:

919.16 Mio. EUR

Unternehmenswert:

970.78 Mio. EUR

Umsatz:

EBITDA:

-153.69 Mio. EUR

Nettogewinn:

-171.71 Mio. EUR

Gewinn je Aktie:

-3.26 EUR

Schulden:

141.97 Mio. EUR

Liquide Mittel:

89.51 Mio. EUR

Operativer Cashflow:

-98.8 Mio. EUR

Bargeldquote:

3.36

Umsatzwachstum:

Gewinnwachstum:

8.09%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

KODIAK SCIENCES

Letzte Datenerhebung:

13.11.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 52.82 Mio. St.

Frei handelbar: 92.28%

Leerverk. Aktien: 8.1%

Rückkaufquote: -0.06%

Mitarbeiter: 109

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 10.01%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 14.23

PEG-Ratio: -7.01

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -60.71%

Eigenkaprendite: -140.33%

>Peer Group

Es sind 599 Aktien bekannt.

>KODIAK SCIENCES Chart & Kurs - NASDAQ

>KODIAK SCIENCES News

13.11.25 - 22:06	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results (PR Newswire)
	PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling......

12.11.25 - 23:51	Kodiak Sciences to Present at Upcoming Investor Conferences (PR Newswire)
	PALO ALTO, Calif., Nov. 12, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that Victor Perlroth, M.D., Chief Executive......

12.09.25 - 19:00	Why Is Kodiak Sciences (KOD) Down 1.2% Since Last Earnings Report? (Zacks)
	Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

19.08.25 - 20:21	Kodiak Sciences to Present at American Chemical Society Fall 2025 (PR Newswire)
	PALO ALTO, Calif., Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present the Company's......

13.08.25 - 23:00	Kodiak Sciences Beats Q2 Loss Estimates (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.25 - 22:03	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results (PR Newswire)
	PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial......

25.06.25 - 22:48	Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society (PR Newswire)
	PALO ALTO, Calif., June 25, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management along with......

18.06.25 - 05:01	Insiderhandel: Vorstand verkauft Aktien von Kodiak Sciences im Wert von 2640 USD (Insiderkauf)
	Borgeson, John A. - Vorstand - Tag der Transaktion: 2025-06-17...

13.06.25 - 19:00	Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report? (Zacks)
	Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

30.05.25 - 03:36	Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference (PR Newswire)
	PALO ALTO, Calif., May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.,......

14.05.25 - 23:33	Kodiak Sciences GAAP EPS of $1.09 beats by $1.99 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:18	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results (PR Newswire)
	PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In the first quarter of 2025, we maintained a strong focus on execution. We look forward to......

02.05.25 - 05:45	Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases (PR Newswire)
	PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific......

27.03.25 - 21:03	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
	PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor......

10.03.25 - 21:42	Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy (PR Newswire)
	Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences......

07.01.25 - 12:03	Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
	PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.,......

10.12.24 - 08:06	Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.11.24 - 17:18	Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
	When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?...

14.11.24 - 23:42	Kodiak Sciences GAAP EPS of -$0.84 beats by $0.07 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.24 - 22:01	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results (PR Newswire)
	PALO ALTO, Calif., Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Unter jedem Stein schläft ein Skorpion. - Sub omni lapide scorpius dormit. - Macarius Hieromonachus

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram